Fred B. Craves - Mar 12, 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Stock symbol
MDGL
Transactions as of
Mar 12, 2025
Transactions value $
-$3,800,001
Form type
4
Date filed
3/14/2025, 04:25 PM
Previous filing
Dec 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $112K +1.73K +0.49% $65.06 352K Mar 12, 2025 Direct
transaction MDGL Common Stock Options Exercise $666K +6K +1.71% $111.06 358K Mar 12, 2025 Direct
transaction MDGL Common Stock Sale -$525K -1.59K -0.44% $330.54 356K Mar 12, 2025 Direct F1
transaction MDGL Common Stock Sale -$914K -2.76K -0.77% $331.36 353K Mar 12, 2025 Direct F2
transaction MDGL Common Stock Sale -$792K -2.38K -0.67% $332.38 351K Mar 12, 2025 Direct F3
transaction MDGL Common Stock Sale -$267K -800 -0.23% $333.66 350K Mar 12, 2025 Direct F4
transaction MDGL Common Stock Sale -$67K -200 -0.06% $334.97 350K Mar 12, 2025 Direct F5
transaction MDGL Common Stock Options Exercise $504K +7.74K +2.21% $65.06 358K Mar 13, 2025 Direct
transaction MDGL Common Stock Sale -$629K -1.95K -0.55% $322.45 356K Mar 13, 2025 Direct F6
transaction MDGL Common Stock Sale -$533K -1.65K -0.46% $323.47 354K Mar 13, 2025 Direct F7
transaction MDGL Common Stock Sale -$292K -900 -0.25% $324.69 353K Mar 13, 2025 Direct F8
transaction MDGL Common Stock Sale -$261K -800 -0.23% $325.63 353K Mar 13, 2025 Direct F9
transaction MDGL Common Stock Sale -$328K -1K -0.28% $327.63 352K Mar 13, 2025 Direct F10
transaction MDGL Common Stock Sale -$131K -400 -0.11% $328.68 351K Mar 13, 2025 Direct F11
transaction MDGL Common Stock Sale -$319K -967 -0.28% $329.86 350K Mar 13, 2025 Direct F12
transaction MDGL Common Stock Sale -$24.8K -75 -0.02% $330.23 350K Mar 13, 2025 Direct
holding MDGL Common Stock 11.2K Mar 12, 2025 See Footnote F13
holding MDGL Common Stock 1.26K Mar 12, 2025 See Footnotes F14
holding MDGL Common Stock 21K Mar 12, 2025 See Footnotes F15

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -1.73K -18.25% $0.00 7.74K Mar 12, 2025 Common Stock 1.73K $65.06 Direct F16
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -6K -100% $0.00 0 Mar 12, 2025 Common Stock 6K $111.06 Direct F16
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -7.74K -100% $0.00 0 Mar 13, 2025 Common Stock 7.74K $65.06 Direct F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive.
F13 Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
F14 These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
F15 Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
F16 The shares underlying this stock option are fully vested and exercisable.